BridgeBio Oncology Therapeutics is recovering technically with momentum just clearing its recovery threshold, but quality metrics below the engine's floor, a confirmed downtrend, and a rejected implausible analyst target argue for caution even though analysts elsewhere model substantial upside.
Thesis pillars
- Implausible Analyst Target Rejected→Stable
- Momentum Recovering Soft Warning→Stable
- Quality Below Floor Cash Burning→Stable
- +2 more pillars — see the Why tab for full reasoning
BridgeBio Oncology Therapeutics (BBOT) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend.
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotechnology company developing small-molecule inhibitors targeting RAS and PI3Kα-driven cancers. Its pipeline includes BBO-8520 (dual ON/OFF KRAS G12C inhibitor) and BBO-11818 (pan-KRAS ON/OFF inhibitor) in Phase 1... Read more
Sell if holding. Engine safety override at $8.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Score 4.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About BridgeBio Oncology Therapeutics
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is advancing three clinical-stage cancer therapies in Phase 1 trials: BBO-8520 and BBO-11818, dual ON/OFF KRAS inhibitors targeting G12C, G12D, and G12V mutations in solid tumors including non-small cell lung cancer, and BBO-10203, a RAS:PI3Kα breaker for HER2-positive and hormone-receptor-positive breast cancer and KRAS-mutant colorectal cancer. The company disclosed encouraging preliminary data across all three programs in January 2026, competing against FDA-approved KRAS G12C drugs sotorasib (2021) and adagrasib (2022), which target only the inactive OFF state of the protein.
BBOT has never generated product revenue and does not expect to for several years, if ever; the company posted a $134.0 million net loss in 2025 against a $356.6 million accumulated deficit, financed principally through private placements of securities since its 2016 incorporation and 2024 transition to independent operations. Its pipeline strategy centers on internal combination potential: because BBO-10203 blocks RAS-driven activation of PI3Kα without the hyperglycemia side effects that have limited earlier PI3Kα inhibitors, BBOT plans to combine it with its own KRAS inhibitors, BBO-8520 and BBO-11818, rather than relying on external combination partners, an approach the company says could address the MAPK and PI3Kα-AKT pathways simultaneously in KRAS-mutant tumors. In April 2026, Chief Scientific Officer Pedro Beltran became President and CEO, succeeding Eli Wallace, who continues advising the company as a consultant.
Show full overview
All three of BBOT's near-term catalysts land in the same window: the company expects additional clinical data from ONKORAS-101, KONQUER-101, and BREAKER-101 in the second half of 2026, meaning a single disappointing readout cycle could simultaneously cloud the outlook for all three programs rather than just one. BBOT also faces direct competition from other companies developing ON/OFF or tricomplex KRAS inhibitors, such as Revolution Medicines' RMC-6291, against which BBOT has already run head-to-head preclinical comparisons, underscoring that its differentiation claim rests on maintaining a potency and safety edge that has yet to be confirmed in larger clinical populations.
See also: Healthcare · Biotechnology
From BridgeBio Oncology Therapeutics's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02MEDIUMPresident and CEO Eli Wallace resigned as CEO and Class III director effective April 20, 2026, with no disagreement with the company cited; he continues as an advisor/consultant. Chief Scientific Officer Pedro Beltran was appointed successor President, CEO, and Class III director effective the same date.SEC filing →
- 2026-06-22Item 5.02LOWDirector Michelle Doig resigned from the Board upon completion of her term as a Class I director, effective June 16, 2026 (the date of the Annual Meeting). No disagreement with the company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $7.84. Score 4.9/10, moderate confidence.
Take-profit target: $21.85 (+159.2% upside). Prior stop was $7.84. Stop-loss: $7.84.
Quality below floor (1.7 < 4.0).
BridgeBio Oncology Therapeutics trades at a P/E of N/A (forward -3.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover BBOT with a consensus score of 4.3/5. Average price target: $25.
What does BridgeBio Oncology Therapeutics do?BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotechnology company developing small-molecule inhibitors...
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotechnology company developing small-molecule inhibitors targeting RAS and PI3Kα-driven cancers. Its pipeline includes BBO-8520 (dual ON/OFF KRAS G12C inhibitor) and BBO-11818 (pan-KRAS ON/OFF inhibitor) in Phase 1 trials for KRAS-mutant solid tumors including NSCLC, plus BBO-10203, a RAS:PI3Kα breaker in Phase 1 for HER2+ and HR+/HER2- breast cancer and KRAS-mutant colorectal cancer. The company has no approved products or revenue, reporting a $134.0 million net loss in 2025 against a $356.6 million accumulated deficit.